IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab

Publisher： Bentham Science Publishers

E-ISSN： 1875-6360|7|4|288-300

ISSN： 1573-3971

Source： Current Rheumatology Reviews, Vol.7, Iss.4, 2011-11, pp. : 288-300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review

By  

Current Rheumatology Reviews, Vol. 8, Iss. 3, 2012-08 ,pp. : 209-226

Bentham Science Publishers

Access to resources Recommend Favorite

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

By Hirano Toru  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 298-302

Springer Publishing Company

Access to resources Recommend Favorite

The OPTION trial: inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis

By Ramos-Remus Cesar   Muriel-Vizcaino Rodolfo  

Future Rheumatology, Vol. 3, Iss. 5, 2008-10 ,pp. : 429-434

Future Medicine

Access to resources Recommend Favorite

Treatment of Crohn’s disease with anti-IL-6 receptor antibody

By Ito Hiroaki  

Journal of Gastroenterology, Vol. 40, Iss. 16, 2005-01 ,pp. : 32-34

Springer Publishing Company

Access to resources Recommend Favorite

Tocilizumab: a new form of biological therapy for rheumatoid arthritis

By Balint Geza P   Balint Peter V  

Future Rheumatology, Vol. 2, Iss. 4, 2007-08 ,pp. : 361-371

Future Medicine

Access to resources Recommend Favorite